Previous Close | 0.0900 |
Open | 0.0900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0880 - 0.0900 |
52 Week Range | 0.0700 - 0.1700 |
Volume | |
Avg. Volume | 35,505 |
Market Cap | 9.843M |
Beta (5Y Monthly) | 0.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | Jun 12, 2024 - Jun 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for PURE
EL CAJON, Calif., March 18, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.
EL CAJON, Calif., December 14, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2023.
EL CAJON, Calif., October 30, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.